Chemoimmunotherapy for high-risk neuroblastoma

Affiliations

Comment

Brian H Kushner. Lancet Oncol. 2017 Jul.

. 2017 Jul;18(7):845-846.

doi: 10.1016/S1470-2045(17)30337-6. Epub 2017 May 23.

¹ Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: kushnerb@mskcc.org.

No abstract available

Comment on

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.